Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2026 Jan 27:2026:3598919.
doi: 10.1155/bca/3598919. eCollection 2026.

Therapeutic Potential of Sodium Selenite Application for Promoting Radioactive Iodine Avidity in Papillary Thyroid Cancer

Ji Min Oh  1   2 , Ramya Lakshmi Rajendran  1   2   3 , Prakash Gangadaran  1   2 , Chae Moon Hong  1   2   4 , Byeong-Cheol Ahn  1   2   3   4
Affiliations

Therapeutic Potential of Sodium Selenite Application for Promoting Radioactive Iodine Avidity in Papillary Thyroid Cancer

Ji Min Oh et al. Bioinorg Chem Appl. .

Abstract

Objective: Radioactive iodine therapy is a mainstay for recurrent and metastatic differentiated thyroid cancer. However, a substantial portion of differentiated thyroid cancer patients exhibits dedifferentiation status with a lack of sodium iodide symporter functionality and expression, as well as downregulated thyroid-specific proteins and transcription factors. Eventually, this status is connected to the failure of radioactive iodine therapy with an overall poor prognosis. Selenium, an essential trace element, has antitumor, antioxidant, immunomodulatory, and antiviral activities and is required for thyroid hormone synthesis and metabolism, and it was reported that sodium selenite induces radioactive iodine uptake in thyroid tissue in rats. However, the relationship between sodium selenite and differentiation markers in differentiated thyroid cancer remains unclear.

Methods: We investigated whether sodium selenite enhances radioactive iodine avidity and reinforces 131I therapeutic effects in papillary thyroid cancer cells. We also analyzed changes in selected signaling pathways and factors induced by sodium selenite treatment.

Results: Sodium iodide symporter, thyroid-specific proteins, and transcription factors were upregulated by sodium selenite, increasing radioactive iodine avidity and radioactive iodine-mediated cytotoxicity in papillary thyroid cancer cells. Sodium selenite downregulated the MAPK, PI3K-AKT, and GSK-3β/β-catenin signaling pathways.

Conclusion: Sodium selenite may serve as a promising adjunct to enhance radioactive iodine avidity in papillary thyroid cancer cells.

Keywords: papillary thyroid cancer; radioactive iodine avidity; radioactive iodine therapy; sodium iodide symporter; sodium selenite.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

None
(a)
None
(b)
None
(c)
None
(d)
None
(e)
None
(a)
None
(b)
None
(c)
None
(d)
None
(e)
None
(f)
None
(g)
None
(h)
None
(a)
None
(b)
None
(c)
None
(a)
None
(b)
None
(c)
None
(d)
None
(e)
None
(f)
None
(g)
None
(h)
Figure 5
Figure 5
Schematic of increased RAI avidity after sodium selenite treatment in thyroid cancer cells.
See this image and copyright information in PMC

References

    1. Sung H., Ferlay J., Siegel R. L. et al., Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, CA: A Cancer Journal for Clinicians. (2021) 71, no. 3, 209–249, 10.3322/caac.21660. - DOI - PubMed
    1. Oh J. M., Rajendran R. L., Gangadaran P. et al., Targeting GLI1 Transcription Factor for Restoring Iodine Avidity with Redifferentiation in Radioactive-Iodine Refractory Thyroid Cancers, Cancers (Basel). (2022) 14, no. 7, 10.3390/cancers14071782. - DOI - PMC - PubMed
    1. Su D. H., Chang S. H., and Chang T. C., The Impact of Locoregional Recurrences and Distant Metastases on the Survival of Patients with Papillary Thyroid Carcinoma, Clinical Endocrinology. (2015) 82, no. 2, 286–294, 10.1111/cen.12511, 2-s2.0-84921598726. - DOI - PubMed
    1. Durante C., Haddy N., Baudin E. et al., Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine Therapy, Journal of Clinical Endocrinology and Metabolism. (2006) 91, no. 8, 2892–2899, 10.1210/jc.2005-2838, 2-s2.0-33747642244. - DOI - PubMed
    1. Oh J. M. and Ahn B. C., Molecular Mechanisms of Radioactive Iodine Refractoriness in Differentiated Thyroid Cancer: Impaired Sodium Iodide Symporter (NIS) Expression Owing to Altered Signaling Pathway Activity and Intracellular Localization of NIS, Theranostics. (2021) 11, no. 13, 6251–6277, 10.7150/thno.57689. - DOI - PMC - PubMed

LinkOut - more resources